Lior Raviv
Chief Tech/Sci/R&D Officer chez PLURI INC.
Profil
Lior Raviv is currently the Chief Technology Officer at Pluri, Inc. He previously worked as the Head of Research & Development Analytical Researcher at Teva Pharmaceutical Industries Ltd.
from 2010 to 2011.
He also served as the Vice President of Operations & Development at Pluristem Ltd.
Mr. Raviv obtained his undergraduate degree from Ben-Gurion University of the Negev.
Postes actifs de Lior Raviv
| Sociétés | Poste | Début |
|---|---|---|
| PLURI INC. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Lior Raviv
| Sociétés | Poste | Fin |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 01/02/2011 |
Pluristem Ltd.
 Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The private company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Chief Operating Officer | - |
Formation de Lior Raviv
| Ben-Gurion University of the Negev | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| PLURI INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Pluristem Ltd.
Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The private company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Commercial Services |
